Possible erythropoietin pharmacotherapeutic targets on painful diabetic neuropathy in rats
Abstract Erythropoietin is a renal cytokine involved in regulating hematopoiesis. Current evidence indicates that erythropoietin exerts pleiotropic effects in animal models. However, its role in painful diabetic neuropathy, as well as the possible action mechanisms are not yet established. Therefore...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Academia Brasileira de Ciências
2025-02-01
|
| Series: | Anais da Academia Brasileira de Ciências |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0001-37652025000100604&lng=en&tlng=en |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823859188161314816 |
|---|---|
| author | SAMUEL SUAREZ-MENDEZ DEYSI Y. BERMÚDEZ-OCAÑA |
| author_facet | SAMUEL SUAREZ-MENDEZ DEYSI Y. BERMÚDEZ-OCAÑA |
| author_sort | SAMUEL SUAREZ-MENDEZ |
| collection | DOAJ |
| description | Abstract Erythropoietin is a renal cytokine involved in regulating hematopoiesis. Current evidence indicates that erythropoietin exerts pleiotropic effects in animal models. However, its role in painful diabetic neuropathy, as well as the possible action mechanisms are not yet established. Therefore, this was the purpose of our study. Rats were injected with streptozotocin to produce hyperglycemia. The mechanical allodynia was measured by the up-down method using the von Frey filaments in diabetic rats. To determine the action mechanisms of erythropoietin, levels of NF-κB in serum were measured with ELISA and was used L-NAME (Nω-nitro-L-arginine methyl ester hydrochloride, non-selective nitric oxide synthase inhibitor; 0.1-1 mg/kg, i.p.), glibenclamide (ATP-sensitive K+ channels blocker; 1-10 mg/kg, i.p.), methiothepin (non-selective 5-HT receptor antagonist; 0.01-0.1 mg/kg, i.p.) and naloxone (non-selective opioid receptor antagonist; 1 mg/kg). Intraperitoneal administration of erythropoietin (500-4000 UI/kg) prevented allodynia in diabetic rats. Additionally, erythropoietin significantly decreased serum levels of NF-κB during the evaluation of tactile allodynia and L-NAME, glibenclamide and methiothepin, but not naloxone, reverted erythropoietin-induced antiallodynia. These data suggest erythropoietin effect on painful diabetic neuropathy are mediated at least in part, via deactivation of NF-κB, activation of nitric oxide-ATP-sensitive K+ channel pathway as well as the activation of 5-HT receptors. |
| format | Article |
| id | doaj-art-86d9c4e41d62454398c39c8bda15285f |
| institution | Kabale University |
| issn | 1678-2690 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Academia Brasileira de Ciências |
| record_format | Article |
| series | Anais da Academia Brasileira de Ciências |
| spelling | doaj-art-86d9c4e41d62454398c39c8bda15285f2025-02-11T07:42:43ZengAcademia Brasileira de CiênciasAnais da Academia Brasileira de Ciências1678-26902025-02-0197110.1590/0001-3765202520230569Possible erythropoietin pharmacotherapeutic targets on painful diabetic neuropathy in ratsSAMUEL SUAREZ-MENDEZhttps://orcid.org/0000-0002-4295-7033DEYSI Y. BERMÚDEZ-OCAÑAhttps://orcid.org/0000-0002-9750-7670Abstract Erythropoietin is a renal cytokine involved in regulating hematopoiesis. Current evidence indicates that erythropoietin exerts pleiotropic effects in animal models. However, its role in painful diabetic neuropathy, as well as the possible action mechanisms are not yet established. Therefore, this was the purpose of our study. Rats were injected with streptozotocin to produce hyperglycemia. The mechanical allodynia was measured by the up-down method using the von Frey filaments in diabetic rats. To determine the action mechanisms of erythropoietin, levels of NF-κB in serum were measured with ELISA and was used L-NAME (Nω-nitro-L-arginine methyl ester hydrochloride, non-selective nitric oxide synthase inhibitor; 0.1-1 mg/kg, i.p.), glibenclamide (ATP-sensitive K+ channels blocker; 1-10 mg/kg, i.p.), methiothepin (non-selective 5-HT receptor antagonist; 0.01-0.1 mg/kg, i.p.) and naloxone (non-selective opioid receptor antagonist; 1 mg/kg). Intraperitoneal administration of erythropoietin (500-4000 UI/kg) prevented allodynia in diabetic rats. Additionally, erythropoietin significantly decreased serum levels of NF-κB during the evaluation of tactile allodynia and L-NAME, glibenclamide and methiothepin, but not naloxone, reverted erythropoietin-induced antiallodynia. These data suggest erythropoietin effect on painful diabetic neuropathy are mediated at least in part, via deactivation of NF-κB, activation of nitric oxide-ATP-sensitive K+ channel pathway as well as the activation of 5-HT receptors.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0001-37652025000100604&lng=en&tlng=enErythropoietinNF-κBNitric oxidePainful diabetic neuropathyPotassium channelsSerotoninergic receptor |
| spellingShingle | SAMUEL SUAREZ-MENDEZ DEYSI Y. BERMÚDEZ-OCAÑA Possible erythropoietin pharmacotherapeutic targets on painful diabetic neuropathy in rats Anais da Academia Brasileira de Ciências Erythropoietin NF-κB Nitric oxide Painful diabetic neuropathy Potassium channels Serotoninergic receptor |
| title | Possible erythropoietin pharmacotherapeutic targets on painful diabetic neuropathy in rats |
| title_full | Possible erythropoietin pharmacotherapeutic targets on painful diabetic neuropathy in rats |
| title_fullStr | Possible erythropoietin pharmacotherapeutic targets on painful diabetic neuropathy in rats |
| title_full_unstemmed | Possible erythropoietin pharmacotherapeutic targets on painful diabetic neuropathy in rats |
| title_short | Possible erythropoietin pharmacotherapeutic targets on painful diabetic neuropathy in rats |
| title_sort | possible erythropoietin pharmacotherapeutic targets on painful diabetic neuropathy in rats |
| topic | Erythropoietin NF-κB Nitric oxide Painful diabetic neuropathy Potassium channels Serotoninergic receptor |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0001-37652025000100604&lng=en&tlng=en |
| work_keys_str_mv | AT samuelsuarezmendez possibleerythropoietinpharmacotherapeutictargetsonpainfuldiabeticneuropathyinrats AT deysiybermudezocana possibleerythropoietinpharmacotherapeutictargetsonpainfuldiabeticneuropathyinrats |